Experienced in Chronic Obstructive Pulmonary Disease (COPD)

Claus Neurohr

Stuttgart, BW, DE 
Experienced in Chronic Obstructive Pulmonary Disease (COPD)
Stuttgart, BW, DE 
OverviewLocationsClinical Research

Overview

Claus Neurohr practices in Stuttgart, Germany. Mr. Neurohr is rated as an Experienced expert by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Bronchiolitis Obliterans, Pulmonary Hypertension, Idiopathic Pulmonary Fibrosis, Acute Interstitial Pneumonia, and Lung Transplant.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Chronic Obstructive Pulmonary Disease (COPD).

Gender
Male

Locations

Stuttgart, BW, Germany
Other Locations
Gerlingen, NW, Germany
Munich, BY, Germany
Germany, Germany
Tuebingen, BW, Germany
Giessen, HE 35392, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Enrollment Status: Completed
Publish Date: March 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
A European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-3 in Lung Transplant Recipients
A European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-3 in Lung Transplant Recipients
Enrollment Status: Completed
Publish Date: January 18, 2020
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 2 Less Clinical Trials

112 Total Publications

Pulmonary Hypertension Associated with Lung Diseases
Pulmonary Hypertension Associated with Lung Diseases
Journal: Pneumologie (Stuttgart, Germany)
Published: October 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Neurohr's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile